Myrexis, Inc.

Equities

MYRX

US62856H1077

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 10:57:14 2024-04-24 am EDT			5-day change	1st Jan Change
0.0105 ^USD	0.00%		0.00%	+61.54%

2013	Myrexis, Inc. Announces Board Changes	CI
2013	Myrexis, Inc. Announces Change in Address	CI

Myrexis Mulls Acquisitions

May 17, 2012 at 12:00 am EDT

Myrexis, Inc. will review acquisition opportunities to bring new commercial operations. Gerald Bell, Chairman of Myrexis, said, "The board has been evaluating alternatives to increase shareholder value following our decision in February to suspend development activities on the company's pre-clinical and clinical programs." After evaluating the alternatives, the Board has decided to consider the acquisition of one or more commercial assets.

Latest news about Myrexis, Inc.

Myrexis, Inc. Announces Board Changes	13-04-18	CI
Myrexis, Inc. Announces Change in Address	13-02-28	CI
Myrexis, Inc. announced that it has received $0.25 million in funding from Xstelos Holdings, Inc.	13-02-26	CI
Myrexis, Inc. Announces New Board Appointments, Effective February 13, 2013	13-02-20	CI
Myrexis, Inc.(OTCPK:MYRX) dropped from NASDAQ Composite Index	13-01-31	CI
Myrexis, Inc. Appoints Jonathan M. Couchman as Class II Director, President and Chief Executive Officer; Declares Special Cash Distribution	13-01-23	CI
Myrexis, Inc. Announces Settlement Agreement with Alzheimer's Institute of America; Announces Resignation of David W. Gryska as Acting President and Chief Executive Officer, Chief Operating Officer and Member of the Board of Directors	12-12-21	CI
Myrexis Plans To Liquidate Assets After Completion Of Strategic Review	12-11-09	CI
Myrexis, Inc. Announces Earnings Results for the Year Ended June 30, 2012	12-09-13	CI
Myrexis, Inc. Appoints David W. Gryska as Acting Chief Executive Officer on Demise of Richard B. Brewer	12-08-15	CI
Myrexis Mulls Acquisitions	12-05-17	CI
Myrexis, Inc. Announces Management Changes	12-05-11	CI
Myrexis, Inc. Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended March 31, 2012	12-05-10	CI
Myrexis Mulls Strategic Alternatives	12-02-15	CI
Transcript : Myrexis, Inc., Q2 2012 Earnings Call, Feb 09, 2012	12-02-09
Myrexis, Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended December 31, 2011	12-02-09	CI

Chart Myrexis, Inc.

Duration

Period

More charts

Company Profile

Myrexi, Inc. is a development-stage company. The Company was a biopharmaceutical company that generated a pipeline of differentiated drug candidates in oncology and autoimmune diseases. In February 2012, it announced that the Company has suspended development activity on all of its preclinical and clinical programs and retained Stifel Nicolaus Weisel, an investment banking firm, to assist in reviewing and evaluating a full range of strategic alternatives to enhance shareholder value. The Company determines to pursue the acquisition of one or more commercial-stage biopharmaceutical assets, with the goal of building a commercial-stage biopharmaceutical company. The Company operates in pharmaceutical development and related research activities. The Companyâs revenues were derived from research performed in the United States and, all of the Companyâs long-lived assets are located in the United States.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MYREXIS, INC.	+61.54%	362K
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs